Literature DB >> 8849954

Peritonectomy procedures.

P H Sugarbaker1.   

Abstract

Decisions regarding the treatment of cancer depend on the anatomic location of the malignancy and the biologic aggressiveness of the disease. Some patients may have isolated intraabdominal seeding of malignancy of limited extent or of low biologic grade. In the past these clinical situations have been regarded as lethal. We have used the cytoreductive approach to achieve long-term disease-free survival in some patients with peritoneal carcinomatosis, peritoneal sarcomatosis, or mesothelioma. The cytoreductive approach may require six peritonectomy procedures to resect or strip cancer from all intraabdominal surfaces. These are (1) greater omentectomy-splenectomy, (2) left upper quadrant peritonectomy, (3) right upper quadrant peritonectomy, (4) lesser omentectomy-cholecystectomy with stripping of the omental bursa, (5) pelvic peritonectomy with sleeve resection of the sigmoid colon, and (6) antrectomy. These peritonectomy procedures and preparation of the abdomen for early postoperative intraperitoneal chemotherapy are described.

Entities:  

Mesh:

Year:  1996        PMID: 8849954     DOI: 10.1007/978-1-4613-1247-5_15

Source DB:  PubMed          Journal:  Cancer Treat Res        ISSN: 0927-3042


  8 in total

1.  The omentum.

Authors:  Cameron Platell; Deborah Cooper; John M Papadimitriou; John C Hall
Journal:  World J Gastroenterol       Date:  2000-04       Impact factor: 5.742

2.  FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma.

Authors:  Filippo Pietrantonio; Claudia Maggi; Giuseppe Fanetti; Roberto Iacovelli; Maria Di Bartolomeo; Francesca Ricchini; Marcello Deraco; Federica Perrone; Dario Baratti; Shigeki Kusamura; Elena Tamborini; Alessandra Castano; Paola Valentina Consonni; Ilaria Bossi; Cecilia Gavazzi; Massimo Milione; Giuseppe Pelosi; Filippo de Braud
Journal:  Oncologist       Date:  2014-06-20

3.  Cytoreductive Surgery in Combination with HIPEC in the Treatment of Peritoneal Sarcomatosis.

Authors:  Christina Karamveri; Nicolaos Pallas; Dimitrios Kyziridis; Christos Hristakis; Vasileios Kyriakopoulos; Apostolos Kalakonas; Dimitrios Vaikos; Antonios-Apostolos K Tentes
Journal:  Indian J Surg Oncol       Date:  2018-05-19

Review 4.  Extravascular use of drug-eluting beads: a promising approach in compartment-based tumor therapy.

Authors:  Simon Binder; Andrew L Lewis; J-Matthias Löhr; Michael Keese
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

5.  Overall morbidity but not mortality is increased in elderly patients following cytoreductive surgery and HIPEC.

Authors:  Stefan Beckert; Florian Struller; Philipp Horvath; Anya Falcke; Alfred Königsrainer; Ingmar Königsrainer
Journal:  Langenbecks Arch Surg       Date:  2015-08-06       Impact factor: 3.445

6.  Lymphatic and/or blood vessel invasion in gastric cancer: relationship with clinicopathological parameters, biological factors and prognostic significance.

Authors:  José M del Casar; María D Corte; Ana Alvarez; Isabel García; Miguel Bongera; Luis O González; José L García-Muñiz; María T Allende; Aurora Astudillo; Francisco J Vizoso
Journal:  J Cancer Res Clin Oncol       Date:  2007-07-13       Impact factor: 4.553

7.  Experience after 100 patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Authors:  Ingmar Königsrainer; Derek Zieker; Jörg Glatzle; Olivia Lauk; Julia Klimek; Stephan Symons; Björn Brücher; Stefan Beckert; Alfred Königsrainer
Journal:  World J Gastroenterol       Date:  2012-05-07       Impact factor: 5.742

8.  Cytoreductive surgery under aminolevulinic acid-mediated photodynamic diagnosis plus hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from ovarian cancer and primary peritoneal carcinoma: results of a phase I trial.

Authors:  Yang Liu; Yoshio Endo; Takuji Fujita; Haruaki Ishibashi; Toshihiro Nishioka; Emel Canbay; Yan Li; Shun-Ichiro Ogura; Yutaka Yonemura
Journal:  Ann Surg Oncol       Date:  2014-07-24       Impact factor: 5.344

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.